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Patients with high risk salivary gland malignancies are at increased risk of local failure. We
present our institutional experience with dose escalation using hypofractionated stereo-
tactic body radiotherapy (SBRT) in a subset of this rare disease. Over the course of 9 years,
10 patients presenting with skull base invasion, gross disease with one or more adverse
features, or those treated with adjuvant radiation with three or more pathologic features
were treated with intensity-modulated radiation therapy followed by hypofractionated SBRT
boost. Patients presented with variable tumor histologies, and in all but one, the tumors
were classified as poorly differentiated high grade. Four patients had gross disease, three
had gross residual disease, three had skull base invasion, and two patients had rapidly
recurrent disease (≤6 months) that had been previously treated with surgical resection.
The median stereotactic radiosurgery boost dose was 17.5 Gy (range 10–30 Gy) given in a
median of five fractions (range 3–6 fractions) for a total median cumulative dose of 81.2 Gy
(range 73.2–95.6 Gy). The majority of the patients received platinum based concurrent
chemotherapy with their radiation. At a median follow-up of 32 months (range 12–120) for all
patients and 43 months for surviving patients (range 12–120), actuarial 3-year locoregional
control, distant control, progression-free survival, and overall survival were 88, 81, 68, and
79%, respectively. Only one patient failed locally and two failed distantly. Serious late toxi-
city included graft ulceration in one patient and osteoradionecrosis in another patient, both
of which underwent surgical reconstruction. Six patients developed fibrosis. In a subset of
patients with salivary gland malignancies with skull base invasion, gross disease, or those
treated adjuvantly with three or more adverse pathologic features, hypofractionated SBRT
boost to intensity-modulated radiotherapy yields good local control rates and acceptable
toxicity.
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INTRODUCTION
Salivary gland cancers are very rare subset of head and neck cancers
with a diverse spectrum of histologic subtypes and natural his-
tory (1). For those eligible, surgery is the mainstay treatment with
adjuvant radiation recommended in cases of high-grade histolo-
gies, advanced stage, and/or inadequate excision to maximize local
control and overall survival (OS) (2–4). Patients whose tumors
demonstrate base of skull invasion are known to have high rates of
failure rates and stereotactic radiosurgery with gamma knife has
been shown to significantly decrease the risk of failure (5). Sim-
ilarly, for patients with unresectable disease higher failure rates
Abbreviations: DC, distant control; DVH, dose volume histogram; IMRT, intensity-
modulated radiotherapy; LRC, locoregional control; MRI, magnetic resonance
imaging; OS, overall survival; PET/CT, positron emission tomography/computed
tomography; PFS, progression-free survival; RECIST, response evaluation criteria in
solid tumors; SBRT, stereotactic body radiotherapy; SRS, stereotactic radiosurgery.
have been reported (3). Although doses above 66 Gy have been
shown to reduce rates of local failures, local control rates on the
order of 30% have been reported in several series (3, 6).
In 2003, we began stereotactic body radiotherapy (SBRT) dose
escalation for three subcategories of patients: those with skull base
invasion, those treated definitively to gross disease with one or
more adverse features, and those treated adjuvantly with three
or more adverse pathological features. As salivary gland tumors
are considered a radioresistant subset of head and neck cancers,
hypofractionated dose escalation is well-suited based on the radio-
biologic principle that the larger the fraction cell kill, the greater
the probability of disease control (7). SBRT is particularly suitable
for dose escalation due to the rapid radiotherapy dose fall-off with
current image-guided radiotherapy technique. The CyberKnife
SBRT system (Accuray, Inc., Sunnyvale, CA, USA) uses real-time
image guidance for targeting to deliver highly conformal treatment
of sites throughout the head and neck region. In this manuscript,
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we review our experience using SBRT boost with the Cyberknife
system as a means for dose escalation for subsets of salivary gland
tumors with high risk features.
MATERIALS AND METHODS
ELIGIBILITY
After research ethics board approval was obtained, all patients
with a diagnosis of salivary gland tumors treated with convention-
ally fractionated external beam radiotherapy followed by SBRT
boost treated between 2003 and 2012 with definitive intent at our
institution were retrospectively reviewed. Patients included were
those who were inoperable and received treatment as definitive
radiotherapy or received surgery for their primary tumor with
macroscopic (R2) or microscopic (R1) residue and/or perineural
or skull base invasion. The type and extent of surgery were depen-
dent on the primary site, surgeon’s clinical judgment, and patient’s
willingness to undergo resection. All except for one patient (no. 7
in Table 1) had histologically confirmed diagnosis of high-grade
salivary gland malignancy, and all had available a history of present
illness; a physical examination; diagnostic CT scans of the neck
and chest; positron emission tomography computed tomography
(PET/CT) imaging; and brain magnetic resonance imaging (MRI).
Patients who had undergone prior radiotherapy were excluded.
Charts were reviewed to determine patterns of disease failure,
toxicity, and outcome. Before the treatment, patients’ cases were
reviewed at the multidisciplinary head and neck tumor board.
Radiosensitizing concomitant chemotherapy was administered at
the discretion of the treating medical oncologist.
IMRT TREATMENT PLANNING
Intensity-modulated radiotherapy (IMRT) treatment planning
was delivered as previously described (8). Simulation CT, PET/CT,
and pre- and post-operative MRI were fused for treatment plan-
ning purposes. GTV was contoured for any gross disease and the
PTV consisted of GTV plus 1.5–2 cm margin. In cases of complete
resection, the tumor bed was identified as the CTV and a 1–2 cm
expansion to PTV was created. Elective nodal irradiation was at
the discretion of the radiation oncologist, but generally followed
the published criteria for estimating of risk of nodal involvement
(4, 9). In post-operative cases, the treatment always started within
7–12 weeks from the date of surgery.
RADIOSURGERY TREATMENT PLANNING
Planning for the radiosurgery boost began within 1 week of treat-
ment. A fine cut (1.25 mm) CT was used for targeting and treat-
ment planning. PET/CT and MRI fusion was done on all patients
and used in defining the GTV. SBRT treatment planning was
done as previously described, but adjustments were made by the
treating physician based on tumor location and proximity of crit-
ical structures (10, 11). Three-dimensional non-coplanar beam
arrangements were custom designed for each case to deliver highly
conformal prescription dose distributions. Generally, more beams
were used for larger lesions. As such, prescription lines covering
the PTV were typically around 80% but ranging between 60 and
90% line rather than the more traditional 95–100%. Higher iso-
doses (“hotspots”) were manipulated to occur within the target
and not in adjacent normal tissue. The following critical structures
were contoured: spinal cord, brainstem, optic nerves, optic chiasm,
orbits, lenses, cochlea, contralateral parotid, larynx, and brachial
plexus (when the neck was included). As a general rule, prescrip-
tion doses were dictated by tolerance of surrounding structures,
which were in accordance with the AAPM Task Group 101 (12).
BED was calculated for the IMRT and SBRT portions of the treat-
ment using the formula [BED= nd(1+ d/α/β)], where n is the
number of fractions and d is the dose per fraction, and using an
α/β ratio of 10 for acute reacting tissues. The cumulative BED was
established by combining the calculated BED of IMRT and SBRT.
TOXICITY EVALUATION AND FOLLOW-UP
Acute and late toxicity was defined according to the National Can-
cer Center Institute Common Terminology Criteria for Adverse
Events, version 4.0, and determined by retrospective chart review.
Acute toxicity was defined as occurring within 90 days of treat-
ment completion. A complication that occurred during treatment
that persisted after 90 days was also considered late toxicity. Reg-
ular follow-up is carried out 6 weeks post treatment, and every
2–3 months in the second year by the multimodality treatment
team at our institution thereafter, and then in six monthly intervals
including fibreoptic examination and imaging with MRI and/or
PET/CT scan.
STATISTICAL ANALYSIS
Progression-free survival (PFS), locoregional control (LRC), and
OS were defined as described (10). Disease response was assessed
according to the response evaluation criteria in solid tumors
(RECIST) (13). Survival outcomes were evaluated using the
Kaplan Meier method. All analyses were performed in SAS version
9.2 (SAS Institute Inc., Cary, NC, USA).
RESULTS
PATIENT AND TREATMENT CHARACTERISTICS
Patient characteristics and treatment results are shown in Table 1.
The median age was 69 (16–86) with seven males and three
females. All tumors were of parotid origin except for one sub-
mandibular tumor (no. 1 in Table 1). Patients presented with
variable tumor histologies, and in all but one tumor, they were
classified as poorly differentiated/high grade. Patient no. 7 had low
grade classification, but he recurred 6 months after his first resec-
tion and had gross residual disease following his second resection.
Four patients had gross disease (no. 2, 6, 8, 10), three had gross
residual disease (no. 5, 7, 9), and three had skull base invasion (no.
5, 6, 10). Four patients presented with N0 disease, but in three of
those (patients no. 1, 3, and 5 in Table 1) the nodes were elec-
tively included. Two patients (patients no. 7 and 9 in Table 1) had
rapidly recurrent disease (≤6 months) that had been previously
treated with surgical resection and underwent re-operation with
radical resection followed by adjuvant radiation with SBRT boost.
The rationale for SBRT boost is included in Table 1.
All patients underwent IMRT followed by SBRT boost.
Figures 1 and 2 show representative cumulative dose distribu-
tion and dose volume histograms (DVHs) of critical structures
for an 80-year-old patient with SCC histology who underwent
definitive RT with concurrent cetuximab for a Stage T4bN2b squa-
mous cell carcinoma of the parotid. The median IMRT dose was
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Table 1 | Initial patient characteristics and treatment results.
No. Age Gender Histology/
site
Stage SRS Vol. Surgery Reason for boost IMRT dose/no.
of fractions
SRS dose/no.
of fraction
Cum
dose
cCRT POF Time to
failure
OS Status
1 52 F ACC/SM T2N0M0 301.4 R1 PM, HG, SM origin 58.2/32 15.0/3 73.2 None N/A – 120 Alive, NED
2 68 F PDC/P T3N2M0 8.6 None GD, HG 75.6/42 20.0/5 95.6 Carbo. N/A – 40 Alive, NED
3 47 M Adenoca/P T2N0M0 21.3 R1 PM, PNI, HG 63.0/35 11.25/5 74.3 None N/A – 46 Alive, NED
4 55 M SCC/P T4N2bM0 62.3 R1 SKI, HG 72.0/40 10.0/5 82.0 Cisplatin N/A – 82 Alive, NED
5 63 M Adenoca/P T4aN0M0 5.2 R2 GRD, SKI, HG 66.6/37 10.0/5 76.6 Carbo. N/A – 48 Alive, NED
6 80 F SCC/P T4N2bM0 457.0 None GD, SKI, HG 50.0/25 25.0/5 75.0 Cetux. N/A – 12 Alive, NED
7 16 M Adenoca/P T2N0M0 230.0 R2 GRD, RR 63.0/35 21.0/3 84.0 None N/A – 22 Alive, NED
8 86 M SCC/P T2N2bM0 132.4 None GR, HG 50.4/38 30.0/6 80.4 None Local 15 23 DOD
9 51 M Adenoca/P T3N2bM0 626 R2 GRD, HG, RR 66.6/37 20.0/4 86.6 Carbo. Distant 24 24 Alive with
metastatic
disease
10 66 M Carc. Ex Pleo. T4N3M0 460 None GRD, SKI, CE 75.6/42 10.0/5 85.6 Carbo. Distant 5 6 DOD
The unit for dose is in Gy.
ACC, adenoid cystic carcinoma; Adenoca, adenocarcinoma; Carc. Ex Pleo, carcinoma ex pleomorphic; Carbo, carboplatin; CE, carotid encasement; Cis, cisplatin; Cetux, cetuximab; cCRT, concurrent chemoradio-
therapy; Cum Dose, cumulative dose; DOD, died of disease; GD, gross disease; GRD, gross residual disease post resection; HG, high grade; NED, no evidence of disease; OS, overall survival; SM: SKI, skull base
invasion; submandibular; PDC, poorly differentiated carcinoma; P, parotid; PM, positive margins; PNI, perineural invasion; POF, pattern of failure; RR, rapidly recurrent; SBRT Vol, stereotactic radiosrugery volume;
SCC, squamous cell carcinoma.
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FIGURE 1 | Representative cumulative dose distribution of IMRT
followed by SBRT plan of patient no. 6 ofTable 1 who was treated
definitively to gross disease with concurrent cetuximab for a Stage
T4bN2b squamous cell carcinoma of the parotid. (A,B) Representative
axial views at the base of skull and the parotid gland. (C,D) Representative
coronal and sagittal views. The outer brown isodose line represents the
70 Gy line, followed by the 75 Gy line in green, and 80 Gy in yellow. The
innermost dark brown shaded area represents the planned treatment
volume (PTV). The dark green contoured volume represents the
brainstem.
64.8 Gy (range 50–75.6) given in 1.8 Gy fractions in the majority
of cases except one (patient no. 6), who received 2 Gy fractions.
The median SBRT boost dosage per fraction was 4.5 Gy (range
2–7 Gy) given in a median of five fractions (range 3–6 fractions)
for a total SBRT boost dose of 17.5 Gy (range 10–30 Gy) and a
total median cumulative dose of 81.2 Gy (range 73.2–95.6 Gy). The
median cumulative BED10 was 97.25 Gy (range 88.10–117.20 Gy)
and the median cumulative BED3 was 143.8 Gy (range 120.5–
167.6 Gy). The median interval between IMRT and initiation of
SBRT boost was 1 week (range 0–2 weeks). The majority of the
patients received concurrent chemotherapy with their radiation
(Table 1). Carboplatin was the most administered chemother-
apy, although cisplatin was used in one patient and Cetuximab
in another.
SURVIVAL OUTCOMES AND PATTERN OF FAILURES
A summary of survival outcomes is shown in Table 2 and Figure 3.
At a median follow-up of 29 months (range 12–120 months) for
all patients and 43 months for surviving patients (range 12–
120 months), actuarial LRC, distant control (DC), PFS, and OS
were 88, 81, 68, and 79%, respectively (Table 2, Figure 2). Median
values were not reached for any of the survival outcomes. Only
one patient (no. 8 in Table 1) failed locally 15 months after the
end of his radiation. He enrolled in phase I targeted biologic
trials with local progression of his disease and died 8 months
later. Two patients (no. 9 and 10 in Table 1) developed dis-
tant metastases. One died of disease progression and the other
continues to receive palliative radiation therapy and systemic
chemotherapy/biologics.
TOXICITY
Acute toxicities included mucositis, dysguesia, skin toxicity, and
odynophagia. Generally, the acute symptoms were managed with
palliative treatments such as skin creams, mouth wash, narcotics,
and nutritional support. There were no grade IV or V toxicities or
unexpected acute toxicities. None of the patient required feeding
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FIGURE 2 | (A) Cumulative dose volume histograms (DVHs) of PTV and
critical structures showing from left to right, PTV (red), brainstem (green),
optic chiasm (yellow), and left optic nerve (blue). (B) SBRT DVHs for the
corresponding structures shown in (A). According to the TG 101 (12) SBRT
tolerance for the brainstem is a maximum point dose of 25 Gy in five
fractions and <5 cc of the brainstem receiving 6.6 Gy/fraction. The tolerance
for the optic pathways is a maximum point dose of 25 Gy in five fractions.
tube placement, and there were no treatment related deaths. Long-
term toxicity included hypothyroidism in two patients (no. 1 and
3 in Table 1), sensorineural hearing loss on the affected side in four
patients (no. 2, 3, 5, and 6 in Table 1), overnight xerostomia in three
patients (no. 3, 4, and 5 in Table 1), and fibrosis in six patients (no.
3, 4, 5, 7, 8, and 9 in Table 1), which was managed with physical
Table 2 | Crude survival outcomes.
Median follow-up in months (range) 29 (5–115)
Median follow-up surviving patients in months (range) 37 (6–115)
Actuarial 3-year locoregional control (failed/controlled) 88% (1/9)
Actuarial 3-year progression-free survival (failed/controlled) 64% (3/7)
Actuarial 3-year overall survival (dead/alive) 77% (2/8)
Actuarial 3-year distant control (failed/controlled) 80% (2/8)
Median values were not reached for any of the survival outcomes.
therapy in all patients. One patient developed osteoradionecrosis
(no. 4 in Table 1), which was managed with hyperbaric oxygen and
surgical reconstruction. One patient (no. 3 in Table 1) developed
graft ulceration that was surgically reconstructed. Both remain
without evidence of disease at their last follow-up. There were no
patients with facial nerve injuries.
DISCUSSION
In this manuscript, we presented our institutional experience with
subsets of high risk salivary gland tumors with a high propensity
for local failure (3, 6, 9). This included those with skull base inva-
sion, those treated definitively to gross disease with one or more
adverse features, and those treated adjuvantly with three or more
adverse pathological features. Although these tumors are relatively
rare, the radioresistant nature of these tumors and challenging
location in extremely critical areas in the head and neck make them
an ideal target for dose escalation with stereotactic radiosurgery
boost. Severe hypofractionation such as permitted by SBRT-like
dose-boosting is also thought to radiobiologically counterbalance
the loss of reoxygenation within a few fractions (14).
Douglas et al. showed that for patients with salivary gland neo-
plasms involving the base of skull, treatment with GammaKnife
stereotactic radiosurgery boost, following neutron radiotherapy,
improved local control rates to about 80% at 40 months com-
pared to historical controls receiving neutron therapy alone (5).
Recent results in dose escalation using particle therapy have been
reported (15–17). Pommier et al. treated 23 patients with adenoid
cystic carcinoma and skull base invasion with proton dose escala-
tion to 75.9 Gy (median) in various fractionation schemes with a
reported 5-year LRC rate of 93% (17). Dose escalation with car-
bon ion therapy in a Japanese series including a variety of head
and neck cancers – eight salivary gland tumors of different his-
tologies – showed 100% local control rate at 5 years (16). Most
recently, interim analysis of the German COSMIC trial using dose
escalation with carbon ion boost for salivary gland malignancies
showed tolerable acute toxicities, but the follow-up was too short
for assessment of survival outcomes or late toxicity (15).
Our results show good local control data comparable to
that achieved by Gammaknife radiosurger, although our sample
included more patients with unresectable disease and gross resid-
ual disease (5). The acute and long-term toxicity encountered
in our patient population was clearly tolerable and compara-
ble to other treatment modalities (5, 17, 18). The small sam-
ple size and the retrospective nature of the study prohibit us
from performing any correlational analysis for prognosticators
of late toxicity. In our previously published reirradiation series,
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FIGURE 3 | Survival outcomes at a median follow-up of 29 months for all patients and 37 months for surviving patients. (A) Locoregional control.
(B) Distant control. (C) Progression-free survival. (D) Overall survival.
we reported a correlation between cumulative doses over 90 Gy
and the development of soft tissue necrosis (10). In the RTOG-
MRC randomized trial that showed 67% LRC compared to 13%
in patients with unresectable disease, significant toxicities such as
temporal lobe necrosis, ulceration, and spinal cord myelopathy
were also reported (18). Although Gammaknife dose escalation
following neutron treatment for patients with skull base invasion
did not result in increased toxicity compared to that of neu-
tron alone, there was significant toxicity associated with neutron
treatment overall (5). In the proton dose escalation for patients
with adenoid cystic carcinomas, one patient developed temporal
lobe necrosis (17).
Our DC8 rates also show good results. This could be attributed
to the fact that the majority of our patients received concur-
rent chemotherapy. Tanvetyanon et al. has shown that for locally
advanced or high-grade salivary gland tumors, the addition of
concurrent chemotherapy to post-operative radiation treatment
significantly improves survival outcomes (19). The RTOG 1008 is
currently enrolling patients to address this question.
CONCLUSION
The results of our case series show that, at 3-year follow-up, dose
escalation with SBRT following IMRT results in good local con-
trol for patients with high risk salivary gland malignancies. Further
follow-up is needed as late disease recurrence is not uncommon
for these tumors (20). Our results are also limited by the small
sample size, retrospective nature of the study, and heterogeneity
of the patient population and treatment parameters.
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